BioMarin Pharmaceutical stock (US09061G1013): Q4 2025 earnings beat revenue estimates

BioMarin Pharmaceutical reported Q4 2025 revenue of $874.6 million, surpassing analyst expectations by 4.8%, though EPS missed. The stock fell 2.7% post-earnings to $61.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) released its Q4 CY2025 earnings on May 13, 2026, showing revenue of $874.6 million, up 17% year-over-year and beating analyst estimates of $834.3 million by 4.8%, StockStory as of May 2026. Adjusted EPS came in at $0.46, 17.9% below the $0.56 consensus. The stock traded down 2.7% to $61.21 immediately after the report.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: BioMarin Pharmaceutical Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Rare genetic disorders
• Key revenue drivers: Voxzogo, Vimizim
• Home exchange/listing venue: Nasdaq (BMRN)
• Trading currency: USD

BioMarin Pharmaceutical: core business model

BioMarin Pharmaceutical develops and commercializes therapies for rare genetic disorders, focusing on conditions with limited treatment options, especially in pediatric populations. The company targets unmet needs in biopharma, with products addressing enzyme deficiencies and skeletal dysplasias. This niche positioning allows premium pricing in orphan drug markets, relevant for US investors tracking biotech innovation.

Main revenue and product drivers for BioMarin Pharmaceutical

Voxzogo, approved for achondroplasia, drove significant growth in Q4 2025, contributing to the 17% revenue increase to $874.6 million for the period ended December 31, 2025, published May 13, 2026, StockStory as of May 2026. Legacy products like Vimizim and Naglazyme provide stable cash flows. Full-year 2025 revenue hit around $3.38 billion, aligning with estimates.

Industry trends and competitive position

The rare disease biotech sector benefits from regulatory incentives like orphan drug exclusivity, bolstering BioMarin Pharmaceutical's moat. Competitors include PTC Therapeutics and Sarepta, but BioMarin's diversified portfolio across multiple indications strengthens its US market exposure amid rising gene therapy demand.

Why BioMarin Pharmaceutical matters for US investors

Listed on Nasdaq, BioMarin Pharmaceutical offers US investors direct access to biotech growth in rare diseases, a segment with high barriers and FDA support. Its therapies serve substantial US patient populations, tying performance to domestic healthcare spending trends.

Conclusion

BioMarin Pharmaceutical's Q4 2025 results highlighted revenue strength with a 17% rise, despite EPS and EBITDA shortfalls, setting a $3.38 billion full-year mark. Guidance for 2026 adjusted EPS at $5.05 midpoint trails consensus slightly. The stock's post-earnings dip reflects mixed metrics, with ongoing Voxzogo momentum in focus for biotech watchers.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.